Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Core Laboratories (CLB) Shares Outstanding (2022 - 2026)

Core Laboratories filings provide 5 years of Shares Outstanding readings, the most recent being $46.0 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding fell 1.96% to $46.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $46.0 million, a 1.96% decrease, with the full-year FY2025 number at $47.0 million, changed 0.0% from a year prior.
  • Shares Outstanding hit $46.0 million in Q1 2026 for Core Laboratories, roughly flat from $46.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $47.0 million in Q4 2024 to a low of -$20693.0 in Q2 2023.
  • Median Shares Outstanding over the past 5 years was $46.8 million (2022), compared with a mean of $40.9 million.
  • Biggest five-year swings in Shares Outstanding: increased 0.76% in 2023 and later dropped 1.96% in 2026.
  • Core Laboratories' Shares Outstanding stood at $46.6 million in 2022, then rose by 0.66% to $46.9 million in 2023, then grew by 0.06% to $47.0 million in 2024, then changed by 0.0% to $47.0 million in 2025, then fell by 1.96% to $46.0 million in 2026.
  • The last three reported values for Shares Outstanding were $46.0 million (Q1 2026), $47.0 million (Q4 2025), and $46.1 million (Q3 2025) per Business Quant data.